Enliven Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

ELVN$51.55+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of	As of
	March 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$101,705	$124,117
Marketable securities	187,850	189,323
Restricted cash	—	54
Prepaid expenses and other current assets	4,763	4,633
Total current assets	294,318	318,127
Property and equipment, net	404	458
Operating lease right-of-use assets	651	—
Other long-term assets	7,197	7,175
Total assets	$302,570	$325,760
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,562	$1,342
Accrued expenses and other current liabilities	12,410	14,573
Total current liabilities	13,972	15,915
Long-term liabilities	302	—
Total liabilities	14,274	15,915
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none	—	—
Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 49,038,730 and 48,936,459 atMarch 31, 2025 and December 31, 2024, respectively	49	49
Additional paid-in capital	560,279	553,213
Accumulated other comprehensive (loss) income	(16)	55
Accumulated deficit	(272,016)	(243,472)
Total stockholders’ equity	288,296	309,845
Total liabilities and stockholders' equity	$302,570	$325,760

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.